$64 Million

Lion Biotechnologies

Follow-on Offering

Bookrunner, February 2015

Confidentially Marketed Public Offering

Iovance Biotherapeutics Inc (fka Lion Biotechnologies) operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient.